GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
GALECTIN THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.13 (-3.45%)
Close on Oct 19, 2026
- Market cap
- $230.23M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.50 (−29.96%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $230.23M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$27.84M
- EPS, diluted
- -$0.44
- Book value per share
- -$2.10
- Diluted shares
- 66M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$15.62M
Net income
-$27.84M
EPS, diluted
-$0.44
Free cash flow
–
Reported periodTrailing twelve months